Lumora Attracts Series B Funding.

26 May 2011

Lumora Ltd, the Molecular diagnostics company, developing next generation tests through its proprietary BART Technology platform, has secured £1.5 million from the completion of the company’s latest funding round, led by Catapult Venture Managers Ltd.

The capital injection will primarily be used to accelerate Cambridgeshire-based Lumora’s entry into the clinical molecular diagnostic market, which is already valued at $6 billion and has the potential for explosive growth in emerging markets. The company’s development programmes focus on applications which benefit from the robust, affordable, easy-to-use nature of their core technology, such as an integrated testing station for gastrointestinal (GI) infections and an HIV viral load monitoring system to support drug therapy in the developing world.

Click here for full press release